Sanofi, touting new data, sees 'best-in-class' case for Dupixent in pediatric asthma

Sanofi's Dupixent is already off and running in several key markets—including eczema and adult asthma—and churning up blockbuster sales. Now, with a potential FDA approval in childhood asthma forthcoming, Sanofi is touting new data that could make the medicine a "best-in-class" treatment for those patients.